These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

307 related articles for article (PubMed ID: 38932203)

  • 1. The Use of Broadly Neutralizing Antibodies (bNAbs) in HIV-1 Treatment and Prevention.
    Thavarajah JJ; Hønge BL; Wejse CM
    Viruses; 2024 Jun; 16(6):. PubMed ID: 38932203
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Broadly Neutralizing Antibodies for HIV-1 Prevention.
    Walsh SR; Seaman MS
    Front Immunol; 2021; 12():712122. PubMed ID: 34354713
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Broadly neutralizing antibodies for HIV prevention: a comprehensive review and future perspectives.
    Mahomed S
    Clin Microbiol Rev; 2024 Jun; 37(2):e0015222. PubMed ID: 38687039
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Rare Mutation in an Infant-Derived HIV-1 Envelope Glycoprotein Alters Interprotomer Stability and Susceptibility to Broadly Neutralizing Antibodies Targeting the Trimer Apex.
    Mishra N; Sharma S; Dobhal A; Kumar S; Chawla H; Singh R; Das BK; Kabra SK; Lodha R; Luthra K
    J Virol; 2020 Sep; 94(19):. PubMed ID: 32669335
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adeno-associated virus gene delivery of broadly neutralizing antibodies as prevention and therapy against HIV-1.
    Lin A; Balazs AB
    Retrovirology; 2018 Oct; 15(1):66. PubMed ID: 30285769
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neutralizing antibodies for HIV-1 prevention.
    Julg B; Barouch DH
    Curr Opin HIV AIDS; 2019 Jul; 14(4):318-324. PubMed ID: 31082819
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adeno-Associated Viral Vector Mediated Expression of Broadly- Neutralizing Antibodies Against HIV-Hitting a Fast-Moving Target.
    Sherpa C; Le Grice SFJ
    Curr HIV Res; 2020; 18(2):114-131. PubMed ID: 32039686
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Broadly neutralizing antibodies targeting HIV: Progress and challenges.
    Paneerselvam N; Khan A; Lawson BR
    Clin Immunol; 2023 Dec; 257():109809. PubMed ID: 37852345
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Broadly neutralizing antibodies for the treatment and prevention of HIV infection.
    Caskey M
    Curr Opin HIV AIDS; 2020 Jan; 15(1):49-55. PubMed ID: 31764199
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Emergence of broadly neutralizing antibodies and viral coevolution in two subjects during the early stages of infection with human immunodeficiency virus type 1.
    Sather DN; Carbonetti S; Malherbe DC; Pissani F; Stuart AB; Hessell AJ; Gray MD; Mikell I; Kalams SA; Haigwood NL; Stamatatos L
    J Virol; 2014 Nov; 88(22):12968-81. PubMed ID: 25122781
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Broadly neutralizing antibodies against HIV-1 and concepts for application.
    Gruell H; Schommers P
    Curr Opin Virol; 2022 Jun; 54():101211. PubMed ID: 35306354
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Single-Chain Variable Fragments of Broadly Neutralizing Antibodies Prevent HIV Cell-Cell Transmission.
    van Dorsten RT; Reh L; Trkola A; Morris L; Moore PL
    J Virol; 2022 Feb; 96(4):e0193421. PubMed ID: 34935437
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Can Broadly Neutralizing HIV-1 Antibodies Help Achieve an ART-Free Remission?
    Hsu DC; Mellors JW; Vasan S
    Front Immunol; 2021; 12():710044. PubMed ID: 34322136
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Employing Broadly Neutralizing Antibodies as a Human Immunodeficiency Virus Prophylactic & Therapeutic Application.
    Ding C; Patel D; Ma Y; Mann JFS; Wu J; Gao Y
    Front Immunol; 2021; 12():697683. PubMed ID: 34354709
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical Trials of Broadly Neutralizing Monoclonal Antibodies for Human Immunodeficiency Virus Prevention: A Review.
    Mahomed S; Garrett N; Baxter C; Abdool Karim Q; Abdool Karim SS
    J Infect Dis; 2021 Feb; 223(3):370-380. PubMed ID: 32604408
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antiviral Therapy by HIV-1 Broadly Neutralizing and Inhibitory Antibodies.
    Zhang Z; Li S; Gu Y; Xia N
    Int J Mol Sci; 2016 Nov; 17(11):. PubMed ID: 27869733
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterizing the Relationship Between Neutralization Sensitivity and
    Wilson A; Shakhtour L; Ward A; Ren Y; Recarey M; Stevenson E; Korom M; Kovacs C; Benko E; Jones RB; Lynch RM
    Front Immunol; 2021; 12():710327. PubMed ID: 34603284
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Broadly Neutralizing Antibodies for HIV Prevention.
    Karuna ST; Corey L
    Annu Rev Med; 2020 Jan; 71():329-346. PubMed ID: 31986089
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Positive Selection at Key Residues in the HIV Envelope Distinguishes Broad and Strain-Specific Plasma Neutralizing Antibodies.
    Mabvakure BM; Scheepers C; Garrett N; Abdool Karim S; Williamson C; Morris L; Moore PL
    J Virol; 2019 Mar; 93(6):. PubMed ID: 30567996
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Broadly neutralizing antibodies for treatment and prevention of HIV-1 infection.
    Cohen YZ; Caskey M
    Curr Opin HIV AIDS; 2018 Jul; 13(4):366-373. PubMed ID: 29697469
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.